Jingxi Pharmaceutical

Jingxi Biopharma is a clinical-stage biotechnology company based in Beijing, China, focused on the development of innovative immunotherapies for cancer and autoimmune diseases. The company leverages its proprietary platform to develop small molecule and antibody-based drugs that modulate the innate immune system, with a specific focus on Toll-like receptor (TLR) agonists. Its lead candidate, JX-01, is a potent and selective TLR7 agonist currently in Phase 1 clinical trials for advanced solid tumors. The pipeline also includes JX-02, a TLR8 agonist, and JX-05, an immune-stimulating antibody conjugate (ISAC). Jingxi Biopharma is backed by prominent investors such as Northern Light Venture Capital and Sherpa Healthcare Partners, aiming to address significant unmet needs in precision oncology.